A Study in Healthy Men to Test How Well Different Doses of BI 3821001 Are Tolerated

StatusCompleted
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed
    • Primary and study completion dates changed from estimate of Oct 2, 2026 to Sep 30, 2026
    • Eligibility criteria expanded, about 8 words
  2. Enrollment closed, study ongoing
    • Site details revised
    v3
  3. Recruitment opened
    • Site details revised
    v2
  4. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 3821001 in healthy male trial participants.
Trial Details
NCT Number NCT07526194
Lead Sponsor Boehringer Ingelheim
Conditions
(from sponsor)		 Healthy
Enrollment 72 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov